Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Transplant Cell Ther. 2021 Apr 6;27(7):617.e1–617.e7. doi: 10.1016/j.jtct.2021.03.028

Figure 2.

Figure 2.

Upper age limits for considering alloHCT for patients using myeloablative or reduced intensity/non-myeloablative conditioning regimens.

*One “other” response included “78” years.